What Centrient Pharmaceuticals does

Centrient Pharmaceuticals is a Netherlands-headquartered B2B pharmaceutical manufacturer specializing in sustainable, enzymatically produced antibiotics, next-generation statins, and anti-fungals. Operating from a network of manufacturing sites and sales offices across the Netherlands, Spain, India, China, Mexico, and Singapore, the company is 100% owned by Bain Capital Private Equity following a 2016 acquisition. Centrient supplies Active Pharmaceutical Ingredients (APIs), key intermediates such as 6-APA and 7-ADCA, and Finished Dosage Forms (FDFs) to generic pharmaceutical companies worldwide, with branded product families including Purimox®, Puricillin®, Purilex®, and Puriclor® across penicillin and cephalosporin antibiotics, and atorvastatin and rosuvastatin statins.

The company's core differentiation rests on its proprietary PureActives® enzymatic platform, introduced in 2012 and protected by over 400 patents in approximately 80 patent families. PureActives® replaces the traditional 13-step chemical synthesis process with an enzymatic process operating at ambient temperatures, delivering a 63% reduction in carbon footprint, avoidance of harmful solvents, batch sizes up to 10x larger than competitors, and APIs of measurably higher purity and stability. The technology underpins regulatory positioning as a founding Board Member of the AMR Industry Alliance (2017), a member of the Pharmaceutical Supply Chain Initiative (2016) and Critical Medicines Alliance (2024), and a recipient of BSI Minimized Risk of AMR certification at two manufacturing sites (Santa Perpètua 2024, Toansa 2025) and five consecutive EcoVadis Gold sustainability ratings.

The business model operates on quote-based enterprise pricing across B2B customers including generic drug manufacturers, FDF producers, and generics marketers. Centrient employs approximately 1,800-2,700 people across 14-22 locations in roughly 14 countries, with backward-integrated supply chains spanning intermediates through FDFs. Revenue streams include one-time sales of APIs and intermediates, FDF out-licensing of regulatory dossiers, and ongoing technology licensing under the patent portfolio. The company's strategic posture is anchored on supply security for foundational medicines, regulatory leadership in antimicrobial resistance (AMR), and ESG-driven differentiation versus Asian API competitors, supported by near-term climate targets validated through EcoVadis (46.2% Scope 1/2 and 27.5% Scope 3 emissions reduction by 2031).

Name

Centrient Pharmaceuticals

Legal name

Centrient Pharmaceuticals Netherlands B.V.

Website

https://centrient.com

Company type

Private

Founded year

1874

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Centrient Pharmaceuticals is a Netherlands-based B2B manufacturer of sustainable enzymatic antibiotics, statins, and anti-fungals, supplying APIs, intermediates, and finished dosage forms to global generic pharmaceutical companies under its proprietary PureActives® platform. The company is 100% owned by Bain Capital Private Equity.

Ownership category

akta.pro rank

Product category

Pharmaceutical Ingredients Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

• Active pharmaceutical ingredients
• Enzymatic antibiotic production
• Generic pharmaceutical supply
• Finished dosage forms
• Statins manufacturing

Headquarters

HQ city

Rotterdam

HQ country

Netherlands

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Manufacture and sale of high-quality, sustainable active pharmaceutical ingredients including antibiotics, statins, and anti-fungals using proprietary enzymatic technology.
2. Intermediates: Production of pharmaceutical intermediates including 6-APA and 7-ADCA for beta-lactam antibiotics, providing backward integration and supply chain security.
3. Finished Dosage Forms (FDFs): Supply of finished dosage forms including tablets, capsules, and oral suspensions, with state-of-the-art dossiers available for out-licensing.
4. Technology Licensing: Customers enjoy freedom to operate using enzymatically produced APIs, with technologies protected by over 400 patents.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Centrient Pharmaceuticals manufactures and supplies Active Pharmaceutical Ingredients (APIs), intermediates (6-APA, 7-ADCA), and Finished Dosage Forms (FDFs) for antibiotics (penicillins, cephalosporins), next-generation statins (atorvastatin, rosuvastatin), and anti-fungals (nystatin, caspofungin). The company sells these B2B to generic drug manufacturers worldwide, producing them via its proprietary PureActives® enzymatic technology platform.

Product overview

Centrient Pharmaceuticals is a global business-to-business supplier of sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. The company operates as a single unified pharmaceutical product portfolio consisting of Active Pharmaceutical Ingredients (APIs), intermediates, and Finished Dosage Forms (FDFs). The core proprietary technology is PureActives®, an enzymatic platform introduced in 2012 that produces antibiotics (Penicillins including Amoxicillin and Ampicillin; Cephalosporins including Cephalexin, Cefadroxil, Cefradine, Cefaclor) and statins (Atorvastatin, Rosuvastatin) more sustainably than traditional chemical processes. The antibiotics portfolio also includes key intermediates 6-APA and 7-ADCA, plus isoxazole penicillins (Cloxacillin, Dicloxacillin, Flucloxacillin) and Penicillin G variants. Anti-fungals include Caspofungin and Nystatin variants. FDFs include Amoxicillin standalone and combination products with Clavulanic acid, plus Atorvastatin and Rosuvastatin tablets. All products are marketed as B2B offerings to generic pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

• PureActives®: Proprietary enzymatic platform technology that replaces traditional 13-step production process for antibiotics with more efficient, natural processes requiring less energy and water, avoiding harmful solvents

Products and services

• Purimox (Amoxicillin trihydrate)

Quantifiable outcome

• 63% reduction in carbon footprint compared to traditional chemical process
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Critical Medicines Alliance (CMA)coreStrategic or Co-development Partner · 1 January 2024Joined in 2024 to reinforce commitment to strengthening pharmaceutical supply chain resilience in Europe. CMA was set up by European Union agency HERA to identify priorities for action and strengthen supply of critical medicines in the EU.
• Indian Institute of TechnologyminorStrategic or Co-development Partner · 1 October 2019Partner for STEM programme workshops on antibiotic manufacturing discharge and advanced technologies for removing antibiotic residues from pharmaceutical waste.
• AMR Industry AlliancecoreStrategic or Co-development Partner · 1 May 2017Centrient is a Board Member of the AMR Industry Alliance since its inception in May 2017. The Alliance brings together pharmaceutical companies, generics, diagnostics, and biotech companies to collectively deliver on commitments to curb antimicrobial resistance. Centrient actively participates in developing PNEC targets and manufacturing frameworks.
• Pharmaceutical Supply Chain Initiative (PSCI)coreStrategic or Co-development Partner · 1 November 2016Member since November 2016; PSCI comprises 24 pharmaceutical and healthcare companies promoting responsible supply chain management. Centrient plays a leading role in establishing industry-wide guidelines for responsible antibiotic production.
• Cefic (European Chemical Industry Council)minorStrategic or Co-development PartnerMember of Cefic, a not-for-profit organization representing chemical companies across Europe. Centrient participates in APIC (Active Pharmaceutical Ingredients Committee) for regulatory affairs and quality management.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ACS Dobfar: ACS Dobfar is an Italian-headquartered manufacturer of antibiotics APIs, intermediates (6-APA, 7-ADCA), and finished dosage forms — directly comparable to Centrient's antibiotics-focused portfolio and backward-integrated supply chain model. Both companies serve global generic pharmaceutical customers with beta-lactam and cephalosporin APIs.
• Zhejiang Huahai Pharmaceutical: Zhejiang Huahai is a major Chinese manufacturer of generic APIs including cardiovascular drugs (statins) and finished dosage forms. The company competes directly with Centrient in atorvastatin and rosuvastatin APIs, and represents a key competitor in the global generic API supply chain.
• CSPC Pharmaceutical Group: CSPC is a large Chinese pharmaceutical company with significant API manufacturing operations and an emerging global generics presence. It competes with Centrient in supplying generic APIs to global pharmaceutical companies, particularly in cardiovascular and anti-infective categories.

Broad incumbents

• Aurobindo Pharma: Aurobindo Pharma is one of the world's largest Indian generic pharmaceutical manufacturers with substantial in-house API manufacturing across antibiotics, statins, and antifungals — overlapping directly with Centrient's product portfolio while operating at significantly larger scale across finished dosage forms.
• Sun Pharmaceutical Industries: Sun Pharma is India's largest generic pharmaceutical company with significant API manufacturing capabilities and a global generics portfolio including antibiotics and statins. Comparable to Centrient in product categories served, though operates at much larger scale with direct retail and consumer health exposure.
• Sandoz: Sandoz is the recently spun-off generics division of Novartis and the world's largest generic pharmaceutical company by revenue. It is a major buyer of APIs from companies like Centrient and represents both a key customer and an indirect benchmark for what backward-integrated generics manufacturing looks like at scale.
• Viatris: Viatris (formed from Mylan and Upjohn) is a global pharmaceutical company with a broad generics portfolio and significant API supply relationships. As one of the world's largest generic drug marketers with deep antibiotics exposure, it represents both a customer segment and a comparable player in generic supply chain management.
• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with extensive API manufacturing operations and a leading position in antibiotics and statins. While much larger and more diversified, Teva's API arm provides a benchmark for vertically integrated generic pharmaceutical manufacturing at scale.
• Dr. Reddy's Laboratories: Dr. Reddy's is a major Indian-headquartered generic pharmaceutical company with strong API manufacturing capabilities and a global generics portfolio. Comparable to Centrient in serving global generic pharmaceutical buyers, with direct overlap in antibiotics and statins APIs.
• Apotex: Apotex is the largest Canadian-owned generic pharmaceutical manufacturer with vertically integrated API manufacturing operations and global supply capabilities. The company is a direct customer-competitor in generic APIs and competes in similar supply channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/centrient
• LinkedInlinkedin.com/company/centrient

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centrient Pharmaceuticals